arrow
G

Gregor B. E. Jemec

Herlev-Gentofte Hospital
H指数:101
被引数:4.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HiSQOL-mini: Development and Validation of a Shortened Version of the Hidradenitis Suppurativa Quality of Life (HiSQOL) Instrument

HiSQOL-mini:HiSQOL( Hidradenitis Suppurativa生活质量)量表缩短版的开发与验证

2026-10-210
OAAI
European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment

欧洲HS( hidradenitis suppurativa/ acne inversa)S2k指南第1部分:流行病学、诊断和临床评估

2026-10-030
OAAI
HS-SIQ: A patient-partnered, scar-specific instrument for hidradenitis suppurativa: A pilot report

HS-SIQ:一种患者参与的、针对HS瘢痕的特异性量表:一项试点报告

2026-09-180
PRE
Work impact of immune-mediated inflammatory skin diseases: A systematic review and meta-analysis

免疫介导性炎症性皮肤病的劳动力影响:一项系统评价和荟萃分析

2026-08-110
PRE
Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study

安姆尼吉利单抗治疗 hidradenitis suppurativa 或 palmoplantar pustulosis 的安全性与药代动力学:一项 1b 期研究

2026-07-290
OAAI
Position Statement of the EADV Task Forces With External Experts on Quality of Life Measurement in Hidradenitis Suppurativa: An Update

欧洲皮肤病学与性病学学会工作组与外部专家关于 Hidradenitis Suppurativa 生活质量测量的立场声明:更新

2026-05-170
PRE
Evaluating the diagnostic accuracy of a screening questionnaire for detecting hidradenitis suppurativa: a pooled analysis of accuracy measures from the Global Hidradenitis Suppurativa Atlas (GHiSA) study

评估筛查问卷在检测毛囊角化病方面的诊断准确性:一项基于全球毛囊角化病图谱(GHiSA)研究准确性指标的汇总分析

2026-03-010
PRE
Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa

德尔菲共识: 在化脓性汗腺炎中一线使用生物制剂和小分子

2026-01-240
OAAI
Experiences of Drainage and Associated Impacts: A Qualitative Study Among Patients With Hidradenitis Suppurativa

Hidradenitis Suppurativa患者的引流体验及其相关影响:一项定性研究

2026-01-010
OAAI
Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

Bimekizumab在治疗中度至重度化脓性汗腺炎的患者中,显示出良好的安全性和高水平的疗效,治疗时间长达2年:来自两项III期随机对照试验及其开放标签扩展研究的合并结果

2025-11-150
PRE
Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics

关于使用生物制剂治疗化脓性汗腺炎的升级标准的制定

2025-11-010
OAAI
Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial

Vilobelimab通过在引流隧道上的附加作用改善中重度化脓性汗腺炎的临床结局:SHINE双盲、安慰剂对照随机试验结果

2025-11-011
OAAI